Coherus BioSciences Reaches Clinical and Regulatory Milestones for Udenyca and CHS-201
October 6th 2021Positive findings for Coherus BioSciences' ranibizumab candidate (CHS-201) were presented at the Scientific Meeting of the Retina Society, and the company said equivalence end points were met for an on-body injector version of Udenyca (pegfilgrastim).
Tanvex Presents Positive Findings for Trastuzumab Candidate at ESMO
September 20th 2021Investigators said TX05 met pathologic complete response criteria for equivalence to the originator product, Herceptin. The biosimilar candidate also fell within objective response rate, immunogenicity, safety, and tolerability margins for similarity.
Samsung Bioepis Reports Long-term Ontruzant Findings for HER2-Positive Breast Cancer
September 14th 2021The positive findings for the trastuzumab biosimilar Ontruzant in patients with human epidermal growth factor receptor 2 (HER2)–positive early or locally advanced breast cancer were presented at the European Society for Medical Oncology (ESMO) Congress 2021.